Khaled M. Kotb

Khaled M. Kotb

Auto-generated profile, based on publicly available information

Khaled M. Kotb

Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2024
Verified
Book Chapter
Closed access
PDF file
KKKhaled M. Kotb
Khaled M. Kotb
MSMohamed N. Sharafeldin
Mohamed N. Sharafeldin
HHHamsa Hassan
Hamsa Hassan
ABAchouak Boutalbi
Achouak Boutalbi
AYAhmed Yahya
Ahmed Yahya
ASAmgad E. Salem
Amgad E. Salem
Neurodegenerative diseases include diverse conditions (e.g., Parkinson’s disease and Alzheimer’s disease) in which ongoing loss of neurons and glial cells is implicated. They lead to impaired motor and cognitive functions. Although there is an advancement in therapeutic options impacting the pathogenetic mechanisms of the disease, the BBB exerts a physiological barrier that hinders their access to the brain. Thereby, novel drug delivery approaches have been considered to enhance CNS targeting and bioavailability. There is increasing evidence that lipid-based nanocarriers (e.g., liposomes) may improve brain targeting and ease BBB transportation. Nevertheless, no authorized nanoformula targets the CNS till now. We aim to summarize the relevant literature about the different types of lipid-based nanocarriers and the findings of the preclinical and clinical trials conducted so far through systematic and manual searches in PubMed. Hence, it may be inspiring to translate this approach into clinical practice and benefit from their pharmacokinetic characteristics. Moreover, we attempt to highlight the challenges and future outlooks for their implementation in clinical practice. Overall, it is still early for these applications to be translated into clinical practice due to several reasons, including safety concerns; the lack of simple formulas that can be eligible and allow affordable, large-scale production; and the absence of reliable, high-quality, and strong evidence. We suggest that there is a necessity for appropriately designed controlled trials and standardized analytical methods. <!----> <!----> <!----> <!---->

14 July 2026 in Kidney Medicine
Verified
Journal Article
Open access
EEEnass Elsayed
Enass Elsayed
KKKhaled M. Kotb
Khaled M. Kotb
AHAhmed Heiba
Ahmed Heiba
MEManal Shaker Elhussini
Manal Shaker Elhussini
AEAhmed Abdelmoniem Emara
Ahmed Abdelmoniem Emara
MGMohammed Abdel Gawad
Mohammed Abdel Gawad
Patients receiving hemodialysis (HD) are at increased risk of severe coronavirus disease 2019 (COVID-19) and were prioritized for vaccination, yet vaccine hesitancy remains common. We assessed COVID-19 vaccine knowledge, acceptance, and attitudes among patients receiving HD in Egypt, Kenya, and Cameroon and identified factors associated with vaccine acceptance, prior infection, willingness to receive future doses, and postvaccination complications. Multicenter cross-sectional survey study. Between March 2021 and April 2022, 765 patients receiving maintenance HD and 196 non-dialysis controls were recruited from dialysis centers in Egypt, Kenya, and Cameroon. Sociodemographic characteristics, clinical comorbidities, prior COVID-19, sources of vaccine information, and exposure to vaccinated or infected relatives. COVID-19 vaccine acceptance, willingness to receive future doses, prior infection, and post-vaccination complications. Structured questionnaires assessed knowledge, practices, and attitudes toward COVID-19 vaccination. Multivariable logistic regression identified factors independently associated with study outcomes. Vaccine acceptance was lower among patients receiving HD than nondialysis controls (58.2% vs 96.2%). Fear of side effects was the most common reason for refusal (39.3%). Postvaccination complications were less frequent among patients receiving HD (22.3% vs 44.3%). Hesitancy was more common among women, younger participants, and those with comorbidities or no prior COVID-19. Having vaccinated or previously infected relatives was associated with a greater willingness to receive future doses. Cross-sectional design limits causal inference. Nonprobability sampling and unmatched controls may limit generalizability. COVID-19 cases may have been underreported because of limited testing. COVID-19 vaccine hesitancy among patients receiving HD is driven by fear, misinformation, and sociodemographic factors. Targeted education and improved access to reliable vaccine information may help increase uptake in this population.